Martin Shkreli (above) is a former hedge fund manager and the current CEO of Turing Pharmaceuticals. In August Shkreli bought a drug called Daraprim. It's been around for 62 years and is used to treat toxoplasmosis,
'We need to turn a profit on the drug,' CEO Martin Shkreli said.
Turing Pharmaceuticals LLC CEO Martin Shkreli discusses why the company increased the price of a drug from $13.50 to $750 a tablet. He speaks on "Bloomberg Markets." (Source: Bloomberg)
Once upon a time, Martin Shkreli was an investment professional who made a nice chunk of change by doing things like lobbying the Food and Drug Administration “not to approve certain drugs made by companies whose
Once upon a time, Martin Shkreli was an investment professional who made a nice chunk of change by doing things like lobbying the Food and Drug Administration “not to approve certain drugs made by companies whose